Powering Hearts
Beat to Beat

Abbott's Cardiac Rhythm Management News, Education, and Information Blog

NEW! Assert-IQ™ Insertable Cardiac Monitor (ICM) Cleared by the FDA

Abbott Cardiac Rhythm Management | May 31, 2023
Assert-IQ ICM 5300 ELPlus 3+ years

At the forefront of cardiac care, we here at Abbott are excited to announce that our Assert-IQ™ Insertable Cardiac Monitor (ICM) has been cleared by the FDA

Through this device, we have transformed the detection and management of arrhythmias and have engineered a new experience that provides the best diagnostic solution for your staff and patients. This solution is focused on the areas most meaningful for cardiac monitoring:


See how the Assert-IQ ICM is designed to outperform and built to outlast:


The Assert-IQ ICM’s advanced algorithms reduce false detections by 98.7% for AF and Pause while maintaining 97.7% of true EGMs.1,4,5 Our AF algorithm reduces data burden by 21% compared to the latest version of LINQ II‡*,1-3 and utilizes a five-step AF detection discriminator that focuses on R-R interval patterns and P-Waves in EGMs to verify if an event is true or false.

As the longest lasting Bluetooth®-enabled ICM device, it operates at full functionality beyond six years. Plus, it features remote programmability capabilities that make it easier to adjust parameters, saving valuable time for you and your patients. Here’s how it works:

Advanced Bluetooth® technology checks in every 20 seconds with the connected device to capture, encrypt and transfer patient data to the Merlin.net™ Patient Care Network (PCN) via a connected mobile device with the myMerlin™ Mobile App. A reprogramming request can be initiated and transmitted to a patient through the app quickly and easily – all without the need for an office visit.  

To meet the evolving needs of patients using remote monitoring with an ICM, we are offering two battery life options: 

Assert-IQ ICM 5300 ELPlus 3+ years
Assert-IQ 3+ | May be Preferred for Traditional Cardiac Monitoring.
Assert-IQ ICM 5500 ELPlus 6+ years
Assert-IQ EL+ | Longer Term Monitoring; May be Preferred for AF Management.

The first is a minimum of three years. This may be preferred for more traditional monitoring purposes, such as diagnosing syncope, palpitations or detecting AF in cryptogenic stroke patients. The second is a minimum of six years. This may be preferred for longer-term monitoring of patients, such as those undergoing therapy and at risk of additional arrhythmias

Additional IQ Insights are another exciting new feature of our Assert-IQ™ ICM. These sensors help you make data-driven decisions faster and more confidently. Some of the diagnostics the new sensors capture include: 

Premature Ventricular Contractions (PVCs):

Leading PVC detection algorithms offers the ability to capture consecutive events, including couplets and triplets.6

Elevated Heart Rate with and without Activity:

An ICM first.7-12

Body Position & Posture Changes:

Assess new patient factors to help adjudicate episodes.

Direct Trend Viewer:

Assess AFib Burden, PVCs, Activity Trends,  and MORE!

Assert-IQ ICM provides the best diagnostic solutions for your staff and for your patients who require long-term monitoring. Learn more by visiting the Assert-IQ ICM website and reading this press release

*As of 12.31.22, LINQ IIwith AccuRhythm AI. EGM burden comparison is based on two independent, random, real-world data sets. Patient characteristics and device programming may differ.


  1. Gopinathannair R, Lakkireddy D, Manyam H, et al. Improving the Specificity of Atrial Fibrillation and Tachycardia Detection in an Insertable Cardiac Monitor. Presented at Heart Rhythm Society (HRS); San Francisco, USA; 2022.
  2. Radtke, et al. Artificial Intelligence Enables Dramatic Reduction of False Atrial Fibrillation Alerts from Insertable Cardiac Monitors. Presented at Heart Rhythm Society (HRS); Boston, USA; Aug 2021.
  3. Data on File. Abbott - Report 90986479; AF EGM Burden Reduction in Assert IQ ICM.
  4. Afzal MR, Gopinathannair R, Manyam H, et al. Development and Evaluation of a New Algorithm Enhancement to Improve Specificity of Pause Detection in an Insertable Cardiac Monitor. Presented at Heart Rhythm Society (HRS); San Francisco, USA; 2022.
  5. Data on File. Abbott - Report SJM-CFM-0919-0163.
  6. Manyam H, Afzal MR, Gopinathannair R, et al. Evaluation of A Novel Premature Ventricular Contraction Detection Algorithm in an Insertable Cardiac Monitor. Presented at Heart Rhythm Society (HRS); San Francisco, USA; 2022.
  7. Abbott. Assert-IQ ICM User Manual.
  8. Medtronic. REVEAL LINQLNQ11 Insertable Cardiac Monitor and Patient Assistant PA96000 Clinician Manual. Updated August 26, 2015. Accessed January 17, 2023. https://manuals.medtronic.com/content/dam/emanuals/crdm/CONTRIB_215651.pdf
  9. Medtronic. LINQ II LNQ22 Insertable Cardiac Monitor Clinician Manual. Updated September 01, 2022. Accessed January 17, 2023. https://manuals.medtronic.com/content/dam/emanuals/crdm/M032283C001B_view.pdf
  10. Boston Scientific. User’s Manual, Lux-DxInsertable Cardiac Monitor System M301, 2925, 2935. Updated July 2020. Accessed January 17, 2023. https://www.bostonscientific.com/content/dam/Manuals/us/current-rev-en/92216689-002_LUX-Dx_UM_en_S.pdf
  11. Biotronik. Technical Manual BioMonitor III. Updated December 10, 2020. Accessed January 17, 2023. https://manuals.biotronik.com/emanuals-professionals/?country=US&product=ImplCardMon/BioMonitor3/BioMonitor3_US 
  12. Biotronik. Technical Manual BioMonitor IIIm. Updated December 10, 2020. Accessed January 17, 2023. https://manuals.biotronik.com/emanuals-professionals/?country=US&product=ImplCardMon/BioMonitor3m/BioMonitor3m_US

†As of 12.31.22. Reveal LINQ User Manual, LINQ II User Manual, Lux Dx User Manual, Biomonitor IIIUser Manual, Biomonitor IIIm User Manual


Read More Abbott Cardiac Rhythm Management Articles

Indications, Safety & Warnings

View all Indications, Safety & Warnings

twitter placeholder

Find us on Twitter

Sign up

Receive updates from us

MAT-2305989 v4.0 | Item is approved for U.S. use only